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1. Introduction 
Prostate cancer is the commonest male malignancy diagnosed in countries in the Western 
World and it represents the second commonest cause of male cancer-related death. In the 
United Kingdom in 2008 37,051 new cases of prostate cancer were diagnosed and this 
malignancy resulted in 10,168 deaths. The morbidity and mortality directly attributable to this 
common malignancy is considerable, however in some patients the disease is often relatively 
indolent. Prostate cancer is typically a disease associated with the aging male population 
however in some cases it may be lethal in a younger subset of men. The degree of benefit to be 
gained from diagnosing and treating prostate cancer is directly related to the degree of 
comorbidity and life expectancy of individual men. It is crucial to identify as accurately as 
possible men at increased risk of prostate cancer in order to improve the diagnostic 
performance of a prostate biopsy. Moreover it is important to be able to restrict this invasive 
investigation to men who are likely to benefit from treatment of this malignancy. There are 
currently concerns that Western clinicians and healthcare providers are over-diagnosing large 
numbers of men who would otherwise never have been troubled by their clinically 
undetectable prostate cancer. Moreover there are also concerns that large numbers of men are 
currently being over-treated for their prostate malignancy, resulting in treatment-related 
morbidity including surgical and radiotherapy complications such as erectile dysfunction and 
urinary incontinence. Over the last 25 years urologists and researchers have refined their skills 
sufficiently well to enable accurate diagnosis of a considerable proportion of prostate cancers. 
The contemporary challenge however is to diagnose with increased confidence those 
“clinically significant” cases of prostate cancer which by definition are likely to pose a threat to 
an individual patient if left undetected. The first part of this chapter outlines the current 
predictors of prostate cancer on biopsy including clinical, laboratory and research tools. 
Factors which may help the prediction of prostate cancer on repeat biopsy, as well as current 
diagnostic performance of prediction tools utilising pre- and post-biopsy data to identify men 
at high risk of harbouring clinically significant and aggressive prostate cancer are discussed. 
2. Prediction of prostate cancer on biopsy 
The current method of diagnosing prostate cancer is based upon a triad of digital rectal 
examination (DRE), serum prostate specific antigen (PSA) measurement, and prostate 
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biopsy. Indications for performing a prostate biopsy include an abnormal DRE suspicious 
of malignancy and/or an age-specific abnormal serum PSA. At the present time the 
majority of cases of prostate cancer in the United Kingdom are identified following 
“opportunistic screening” or “case finding” whereby men present to their clinician for one 
of a number of other reasons and then undergo PSA-testing, ideally following appropriate 
and adequate counselling. A smaller proportion of cases are identified following clinical 
presentation with lower urinary tract symptoms or with the symptoms related to 
advanced prostate cancer.  
There are a number of problems and controversies surrounding the diagnosis of early 
organ-confined prostate cancer. Firstly, the PSA test has considerable limitations in its 
sensitivity and specificity (Schroder et al. 2000), and the result can be difficult to interpret, 
particularly for non-urologists. Historically a PSA level below 4 ng/mL was considered to 
be “normal” however over time the upper limits of “normal” PSA were defined in an age-
specific manner (table 1) (Oesterling et al. 1993). 
More recently the results of the Prostate Cancer Prevention Trial (PCPT) (Thompson et al. 
2003) demonstrated that there is no PSA threshold below which one can confidently 
exclude a diagnosis of prostate cancer. The PCPT trial protocol required “normal” men 
with very low levels of PSA to be biopsied at the end of the trial and it was observed that 
39.2% of men with a PSA 2.1-3.0 ng/mL, 27.7% of men with a PSA 1.1-2.0 ng/mL, and 
16.3% of men with a PSA <1.0 ng/mL harboured foci of adenocarcinoma of the prostate 
(Thompson et al. 2003). Indeed in terms of prostate cancer diagnosis and thresholds for 
biopsy, the PCPT trial will be remembered more for this remarkable and intriguing 
observation than for its observations regarding the use of finasteride for prostate cancer 
chemoprevention.  
 
Age (years) PSA ng/mL 
40-49 2.5 
50-59 3.5 
60-69 4.5 
70-79 6.5 
Table 1. Age-specific upper limits of normal PSA. 
Whilst some men with a PSA below the currently accepted “normal” age-specific threshold 
will have prostate cancer, it is also true that many men with a PSA above this threshold will 
not have prostate cancer as an elevated PSA can be attributable to a number of benign 
conditions as well apart from the presence of prostate cancer. Considerable efforts have been 
made to improve the sensitivity and specificity of PSA testing including the adoption of 
free-to-total PSA ratios, %free PSA, [-2]pro-PSA, PSA density and PSA velocity. The 
introduction of these parameters into prostate cancer prediction algorithms can only yield 
modest improvements in the diagnostic accuracy of PSA testing. 
At the present time the recommendation to offer a patient a prostate biopsy in order to 
diagnose early organ confined disease rests with the clinician’s interpretation of the PSA 
result and DRE findings, taking into account the patient’s co-morbidity and life expectancy. 
The final decision to undertake a biopsy is made jointly by the patient and the clinician. This 
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active engagement of the patient in interpreting a particular PSA result can have both 
benefits and negative consequences. It enables the patient to be fully engaged in this 
difficult decision making process. A negative consequence is the generation of a population 
of patients who may be described as the “worried well” i.e. men with a slightly raised PSA 
who have either decided not to have a biopsy or who have had negative biopsies but who 
still have concerns that they might harbour prostate cancer.  
A number of pre-biopsy nomograms for prostate cancer risk assessment have been 
developed by a number of groups to predict the risk of prostate cancer on biopsy and its 
potential for progression. These risk calculators comprise predictive tables and 
nomograms and are widely available in the clinic and on the internet. They aim to aid 
clinicians and patients to decide whether a biopsy is indicated and also may aid treatment 
selection if cancer is found. The use of such nomograms requires the input of each 
individual patient’s clinical data including parameters such as age, race, family history of 
prostate cancer, DRE findings, PSA level, and presence/absence of previous negative 
prostate biopsy (table 2). 
 
 
Table 2. Pre-biopsy risk calculators. 
The Cancer Risk Calculator for prostate cancer (Thompson et al. 2006) may be used to 
predict the probability of detecting prostate cancer, including those with a high Gleason 
Grade. This risk calculator was developed in the USA using a cohort of 5519 men in the 
placebo group of the PCPT who had an initial low PSA ≤3 ng/mL and had an end-of-study 
prostate biopsy after seven years of follow-up. This risk calculator has subsequently been 
adjusted to include the Prostate Cancer Antigen 3 (PCA3) score. PCA3 is a gene encoding a 
non-translated messenger RNA which is over-expressed in prostate cancer (Deras et al. 2008, 
Nomogram Population studied Factors included in nomogram 
Cancer Risk Calculator for 
prostate cancer 
USA 
Race 
Age 
Family history of prostate cancer 
DRE findings 
PSA 
Previous biopsy results (if 
performed) 
Prostate Risk Indicator European 
Risk indicator 1: 
Age 
Family history of prostate cancer 
Urinary symptoms 
Risk indicator 2: 
PSA 
Risk indicator 3: 
PSA 
TRUSS outcome 
DRE findings 
Prostate volume 
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Marks et al. 2007). This test may be useful in evaluating men who already received one set of 
negative prostate biopsies.  
Other adjustments include the incorporation of body mass index, the use of finasteride, 
percentage free PSA and [-2]pro-PSA. It should be noted that the results of the Cancer Risk 
Calculator for prostate cancer may not be applicable to all men as most participants in the 
PCPT were Caucasian,  and results may not be applicable to men of other races. In addition, 
most men in this study underwent a sextant prostate biopsy. This has now been largely 
superseded by an increase in the number of systematic biopsies taken routinely 
(Heidenreich et al. 2010). Moreover, the risk calculator is only applicable to men aged 55 or 
older, without a previous history of prostate cancer and with DRE findings and PSA results 
less than a year old. 
The Prostate Risk Indicator (www.prostatecancer-riskcalculator.com) was developed in 
Rotterdam and consists of 4 risk calculators, of which the first 3 predict the probability of 
detecting a prostate cancer (van den Bergh et al. 2008). This nomogram is based on 6288 
Dutch men enrolled in the European Randomised Study of Screening for Prostate Cancer 
(ERSPC) (Schroder et al. 2009). The risk calculator comprises 4 risk indicators, the first 3 of 
which predict the possibility of a positive prostate biopsy. The first 2 prostate risk indicators 
produced by this group may be used by the general public whereas the other risk 
calculators are intended to be used by urologists during patient evaluation. 
It is likely that future risk calculators developed for predicting prostate cancer risk upon 
performance of a prostate biopsy will incorporate the results of novel molecular 
diagnostic tests such as the detection of prostate cancer specific TMPRSS2-ERG fusion 
genes or Prostate Cancer Antigen 3 (PCA3) in urine sediments. The TMPRSS2-ERG fusion 
gene was discovered to be specifically present in 50% of screened prostate cancer cases 
although there are conflicting observations regarding its association with advanced 
disease (Tomlins et al. 2009). A preliminary study on a limited number of patients had 
shown that the PCA3 test does not perform better than PSA with regards the  
identification of prostate cancer cases (Nyberg et al. 2010). Nevertheless, a multiplex 
model including TMPRSS2-ERG, PCA3, sarcosine and Annexin A3 has been shown to 
significantly improve diagnostic performance for this malignancy with an AUC of 0.86, 
whereas the AUC ranges from 0.66-0.74 for any of these markers when they are used in 
isolation (Cao et al. 2010). At the present time an extensive body of research is being 
conducted with the aim of investigating the potential clinical use of this marker and many 
other molecular biology tests both before and after undertaking a biopsy to diagnose 
prostate cancer (Shappell 2008). 
Genome wide association studies (GWAS) have the capacity to detect low-risk genetic 
susceptibility regions associated with prostate cancer with an increased risk varying 
between 14-52 % (table 3) (Schumacher et al. 2011, Witte 2009). Several recent studies 
incorporating single nucleotide polymorphism (SNP) analyses in models predicting the 
diagnosis of prostate cancer upon biopsy have been published (Wiklund 2010, Aly et al. 
2011, Witte 2009). Using a genetic model including 35 validated SNPs 23% of prostate 
biopsies could be avoided at a cost of missing a prostate cancer diagnosis in 3% of patients 
characterised as having an aggressive disease (Aly et al. 2011). It is hoped that in the future 
these approaches will reduce the number of negative prostate biopsies being performed, 
without reducing the detection of clinically significant prostate cancer. 
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Locus Allele frequency Association 
Chr Region SNP Controls Cases Odds ratio 
2p15 rs721048 0.19 0.21 1.15 
2q37 rs238107965 0.25 0.29 1.14 
3p12 rs2660753 0.1 0.12 1.3 
6q25 rs9364554 0.29 0.33 1.21 
7q21 rs6465657 0.46 0.5 1.19 
8q24 (region 1) rs1447295 0.1 0.14 1.42 
8q24 (region 2) rs16901979 0.04 0.06 1.52 
8q24 (region 3) rs6983267 0.5 0.56 1.25 
10q11 rs10993994 0.38 0.46 1.38 
10q26 rs4962416 0.27 0.32 1.18 
11q13 rs7931342 0.51 0.56 1.21 
12q13 rs902774 0.16 0.19 1.17 
17q12 rs4430796 0.49 0.55 1.22 
17q24 rs1859962 0.46 0.51 1.2 
19q13 rs2735839 0.83 0.87 1.37 
Xp11 rs5945619 0.36 0.41 1.29 
Table 3. Loci associated to prostate cancer and allele frequencies 
Results presented for the most significant SNPs (p<5.108) or those reported in multiple 
studies (Witte 2009, Schumacher et al. 2011). 
3. Prediction of prostate cancer aggressiveness 
At the time of biopsy most patients will have no clinical evidence of either lymph node 
involvement or distant metastasis. Patients with clinically localised disease may be offered 
either a radical treatment or active surveillance, and the choice depends on multiple factors 
reflected by D’Amico risk groups (table 4) (D'Amico et al. 1999). The assessment of the 
pathological stage is critical in decisions regarding appropriate treatment options. Patients 
more likely to have clinically insignificant or indolent prostate cancer may be good 
candidates for active surveillance whereas those with locally advanced disease may benefit 
more from a combined treatment options such as radiotherapy and androgen deprivation 
therapy (Mottet et al. 2011, Heidenreich et al. 2010). 
The prediction of indolent prostate cancer was investigated by Kattan et al. based on criteria 
set by Epstein (Epstein et al. 1994) and defined as organ-confined prostate cancer less than 
0.5cm3 with no Gleason grade over 4. The models were based on clinical variables (serum 
PSA, clinical stage and ultrasound-determined prostate volume) and others derived from 
the analysis of systematic biopsies of the prostate (Gleason grade, percentage of biopsy cores 
involved with cancer, presence of high grade cancer and total length of biopsy cores 
involved). Three models were developed with a c-index ranging from 64% to 79% (Kattan et 
al. 2003) and these validated on an external cohort resulting in a c-index ranging from 61% 
to 76% (Steyerberg et al. 2007). These models provide valuable information when 
counselling patients with prostate cancer who are considering active surveillance. 
www.intechopen.com
 
Prostate Biopsy 68
 PSA Gleason score Clinical stage 
Low risk (all criteria 
present) 
PSA < 10.0 ng/mL 
highest biopsy 
Gleason score 6 
clinical stage 
Tlc or T2a 
Intermediate risk 
(any patient not at 
high or low risk) 
PSA 10 but 
< 20 ng/mL 
highest biopsy 
Gleason score = 7 
clinical stage 
T2b 
High risk (any 
criteria present) 
PSA  20 ng/mL highest biopsy 
Gleason score  8 
clinical stage 
T2c/T3 
Table 4. D'Amico et al risk stratification for clinically localized prostate cancer. 
The local extension of prostate cancer has been investigated using multiple models. The 
Partin tables are the most widely used tool to predict the pathological stage of radical 
prostatectomy specimens based on pre-operative data (Partin et al. 1997), and have been 
updated many times since their creation in 1993 (Partin et al. 2001, Makarov et al. 2007) in 
order to correct for the effects of stage migration. The tables predict organ-confined 
disease, capsular penetration, seminal vesicle infiltration, and pelvic lymph node 
involvement using PSA level, TNM clinical stage, and Gleason score. They were modified 
to predict extra-capsular extension, and can assist the surgeon with decisions regarding 
nerve sparing during surgery (Graefen et al. 2001). This prediction tool was externally 
validated with a discrimination of 70% (Augustin et al. 2004), whilst the prediction of side 
of extra-capsular extension was  accurately undertaken by Ohori et al. with a c-index 
ranging between 79%- to 81% (Ohori et al. 2004). Steuber et al. have also validated this 
prediction tool using an external population resulting in an 84% discrimination figure 
(Steuber et al. 2006) using the following predictors in a logistic regression model: clinical 
stage, pre-treatment PSA, biopsy Gleason sum score and percentage of cores positive for 
cancer in the biopsy specimen. 
Other prognostic factors that may be predicted on prostate biopsy include the presence of 
seminal vesicle involvement (Koh et al. 2003, Gallina et al. 2007) with a c-index of 78% to 
88% or lymph node invasion with a discrimination of 76% (Cagiannos et al. 2003, Briganti 
et al. 2006) Another model may be used to identify with 80% discrimination those patients 
at risk of lymph node invasion beyond the obturator fossa. This prediction tool may be 
useful indeciding whether the patients require an extended lymph node dissection 
(Briganti et al. 2007). 
So far, Genome Wide Association Studies (GWAS) have shown little or no ability to 
discriminate between indolent and fatal forms of prostate cancer and this does not support 
their use in prediction models as reported by Aly (Aly et al. 2011). It is likely that different 
genetic components are involved in the initiation rather than the prognosis of prostate 
cancer and environmental factors may play a stronger role than genetic changes. Ongoing 
studies exploring the association with disease progression and prognosis rather than stage 
at diagnosis, will be more effective in detecting genetic risk factors for prostate cancer 
outcome (Wiklund 2010). 
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4. Evaluation of prediction tools 
Prediction tools are compared using discrimination and calibration. Their use must take into 
consideration their clinical relevance. This can be investigated by assessing their 
generalisability and complexity by making adjustments for competing risks. 
4.1 Discrimination 
Discrimination measures the ability of a predictive tool to discriminate patients according to 
their outcome, for example the presence of prostate cancer versus benign pathology. 
Discrimination is measured using a probability score, with the lowest value being 0.5 (i.e. no 
better than the flip of a coin), and the highest value of 1 representing perfect discrimination 
(i.e. the prediction tool properly identifying the presence or absence of cancer in all 
patients). For binary outcomes such as the presence or absence of cancer, the discrimination 
value is quantified using the area under the curve (AUC). It is also assessed by the c-index 
for censored data (e.g. the time to biochemical recurrence after treatment) or using the Brier 
score (Shariat et al. 2009). 
Prediction models are usually based on clinical, biological or pathological variables that 
impact upon the measured end point. Whilst these models are usually more accurate with 
the inclusion of a greater number of variables, this has to be balanced with the complexity 
of the model and the need to maintain clinical relevance. The risk of occurrence of the 
event of interest may change over time.  For example the risk of observing biochemical 
progression at any time after treatment is highest just after treatment, and decreases with 
the disease free interval. Prediction models therefore need to take these factors into 
account to ensure accuracy. 
4.2 Calibration 
Whereas discrimination is an overall measurement of prediction tool accuracy, the term 
calibration reflects the precision of the test at an individual level. It compares the 
predicted results for each patient with the observed values.  In the case of prostate cancer 
this may be used to predict the presence of a biochemical recurrence. Calibration is 
represented using two curves, one being the ideal curve (45 degree slope line) and the 
other representing the observed test result (figure 1). In an ideal model both curves will 
overlap. It is useful to identify graphically whether the model is well calibrated for all 
events or only for some events. It may be accurate for short term prediction of biochemical 
recurrence, but not for long term prediction of disease outcome (Figure 1). Calibration is 
usually good when applied to the population used to create the prediction model, but not 
necessarily to another population in which the clinical variables may differ. It is therefore 
important that the model is validated on an external population. If the discrimination and 
calibration are similar it is more likely that the predicting model is robust and therefore 
generalizable (Shariat et al. 2009). 
The blue line represents the result of an ideal prediction model. The red line represents time 
to biochemical recurrence observed compared with time to biochemical recurrence 
predicted. Time to recurrence was overestimated at 5 years, and underestimated at 10 years. 
The curve also shows that the model is more accurate in predicting early than late 
recurrence. 
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Fig. 1. Example of calibration curve. 
4.3 Clinical relevance 
4.3.1 Generalizability 
The clinical relevance of a prediction tool depends not only on its intrinsic discrimination 
and calibration performance but also on its generalizability, level of complexity and 
adjustment for competing risks. It is worth noting that any result applies to the population 
analysed, and extrapolation to another population should be used with caution. Where a 
model is more complex and integrates more clinical variables, it is more likely to be 
generalizable since the model usually adjusts the results according to these variables. Before 
using a prediction tool prospectively, it is recommended to test the performance of the 
model on retrospective cohorts. When this approach was applied to populations of patient 
undergoing radical prostatectomy using the Kattan nomogram (Kattan et al. 1998) the 
discrimination varied between 0.67–0.83 (Roupret et al. 2009) indicating a poor 
generalizability. Reduced generalizability may be observed when the stages of cancer at 
diagnosis are different between populations.  
The performance of a predictive tool based on a screened population may differ when used 
on a non-screened population because the stage at diagnosis tends to be higher in the latter 
group of patients (Steyerberg et al. 2007). Another common cause of reduced 
generalizability is the use of models based on a historical cohort of patients treated many 
years previously. Patient characteristics at diagnosis may have changed over time and new 
treatments may have impacted on the target point risk. Once again the validation of recent 
cohorts is necessary unless the prediction model has been modified to take into account the 
differences observed in more recent cohorts (Greene et al. 2004, Shariat et al. 2009). 
4.3.2 Level of complexity 
Another parameter impacting on the clinical relevance of prediction tools is the complexity 
of the model used. Some models are accurate but may require complex algorithms and 
include large numbers of variables. The use of the model will therefore require computer 
support and all variables need to be entered manually, which may be time consuming. Some 
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variables, such as biomarker information, may not be routinely available and the model may 
not be useful in daily clinical practice. One example is the use of PSA kinetics such as PSA 
velocity or doubling time which require several measurements, and PSA density, requiring 
prostate volume information which may not be available routinely (Shariat et al. 2009).  
4.3.3 Adjustment for competing risks 
Predicting the risk of prostate cancer progression may be irrelevant in the presence of 
substantial competing comorbidties which could lead to non cancer-specific mortality 
prior to any progression event. It is therefore of paramount importance to account for 
competing risks in any predictive model. Adjustment is important when there is a 
particular risk of over-treatment where intervention can be associated with significant 
morbidity. (Nielsen et al. 2007).  
4.4 Comparison of existing prediction models 
When new prediction models are developed they should be compared with existing tools and 
validated before they are introduced to routine clinical practice. New prediction tests need to 
be compared to the best current prediction tools using similar populations. These comparisons 
are best made by assessing discrimination and calibration as highlighted earlier in this chapter, 
to offer an unbiased and objective assessment of the new model and it is clinical utility. This 
systematic head-to-head comparison of prediction tools is considered a better approach than a 
simple comparison of the concordance index or the AUC, although the results may be different 
depending on the methods used for comparison (Lughezzani et al. 2010). 
Comparisons of prediction tests should ideally include a decision analysis to assess the 
impact of the prediction tool in clinical practice. One of the most simple and efficient 
methods is a decision curve analysis described previously (Vickers 2008). This method takes 
into consideration the probability of false positives or false negatives. For example, when 
considering the prediction of prostate cancer based on a model, a false positive result 
describes a patient wrongly assigned to have prostate cancer with a negative biopsy result. 
Conversely a false negative result describes a patient wrongly assigned to not having cancer, 
who will be denied a prostate biopsy. These false results are given a harm score, with for 
instance a false negative result for a prostate biopsy with subsequent deleterious delayed 
treatment. This latter situation is considered four-fold more harmful than a false positive 
outcome resulting in an unnecessary prostate biopsy. Clinical consequences of the different 
models can therefore also be compared in terms of the potential harm they may cause. Such 
analysis is best performed during the late stages of model development before the tool is 
implemented clinically (Lughezzani et al. 2010). 
4.5 Prediction tools of the future 
Many of the current prostate cancer prediction tools are imperfect, lack discrimination and are 
often difficult to use in daily clinical practice. The addition of other potentially informative 
clinical and pathological data has not resulted in significant improvement of current models. 
Nevertheless further improvement of existing models is potentially possible by implementing 
imaging data, use of biomarkers, and the use of “smart” electronic medical records. 
Non-invasive imaging in the field of prostate cancer diagnosis, staging and treatment 
planning has gained widespread acceptance in recent years. Magnetic resonance imaging 
(MRI) data has been implemented in several prediction tools in order to accurately identify 
www.intechopen.com
 
Prostate Biopsy 72
organ-confined prostate cancer (Wang et al. 2007) or to detect clinically relevant disease 
(Shukla-Dave et al. 2007), however to date this has not been properly investigated in the 
diagnosis of prostate cancer before biopsy. 
Over the past few years numerous reports identified promising new biomarkers associated 
with the presence of prostate cancer which correlate with its aggressive behaviour (Reed 
and Parekh 2010, Shappell 2008). The introduction of urine and blood biomarkers in 
predictions tools was investigated to predict more accurately disease relapse after radical 
prostatectomy (Shariat et al. 2008a, Shariat et al. 2008b). Clinical practice is currently based 
on the interpretation of a handful of parameters by physicians without automated support, 
but it has been demonstrated that prediction models may perform better than the clinician 
regardless of their levels of expertise (Ross et al. 2002, Walz et al. 2007). Improvements in 
technology now make it possible to assess rapidly large amounts of molecular biology data 
at a greatly reduced cost compared to the recent past. The use of computational algorithms 
to analyse the results of biomarker tests, and the use of evidence-based data to support this 
approach, is likely to improve patient care but this has not yet been confirmed. 
In the future, these algorithms may be incorporated into “smart” electronic medical records 
with the ability to analyse a patient’s individual risk of harbouring clinically significant 
disease, using new and conventional clinico-pathological data such as pathology results which 
will need to be reported as specific fields (e.g. primary and secondary Gleason scores) as well 
as in the conventional manner as a text result. This approach requires modifications of clinical 
practice with the wide implementation of electronic medical records. Algorithms could then be 
refined by merging data from multiple centres with different patient populations, and the 
integration of other investigations such as multiparametric MRI scanning. 
5. Conclusion 
Currently, many parameters can be used to estimate an individual’s risk of harbouring 
prostate cancer on biopsy.  Pre- and post-biopsy factors require further investigation to 
determine whether the cancer detected is potentially aggressive. This is critical to predict 
whether a prostate biopsy is likely to offer real benefit to individual patients, and to guide 
therapeutic options. Despite the multiple limitations described above, predictive tools could, 
in the future provide personalised and evidenced based information, including molecular 
tumour profiling of individual patients to improve the outcome of such a common and 
ubiquitous disease as prostate cancer. 
6. References 
Aly, M., F. Wiklund, J. Xu, W. B. Isaacs, M. Eklund, M. D'Amato, J. Adolfsson & H. 
Gronberg (2011) Polygenic Risk Score Improves Prostate Cancer Risk Prediction: 
Results from the Stockholm-1 Cohort Study. Eur Urol, Vol., No. 2011/02/08, pp. 
Augustin, H., T. Eggert, S. Wenske, P. I. Karakiewicz, J. Palisaar, F. Daghofer, H. Huland & 
M. Graefen (2004) Comparison of accuracy between the Partin tables of 1997 and 
2001 to predict final pathological stage in clinically localized prostate cancer. J Urol, 
Vol. 171, No. 1, 2003/12/11, pp. 177-81. 
Briganti, A., F. K. Chun, A. Salonia, G. Zanni, A. Gallina, F. Deho, N. Suardi, L. F. Da Pozzo, 
L. Valiquette, P. Rigatti, F. Montorsi & P. I. Karakiewicz (2007) A nomogram for 
www.intechopen.com
The Use of Models to Predict the Presence and  
Aggressiveness of Prostate Cancer on Prostate Biopsy 73 
staging of exclusive nonobturator lymph node metastases in men with localized 
prostate cancer. Eur Urol, Vol. 51, No. 1, pp. 112-9; discussion 119-20. 
Briganti, A., F. K. Chun, A. Salonia, G. Zanni, V. Scattoni, L. Valiquette, P. Rigatti, F. 
Montorsi & P. I. Karakiewicz (2006) Validation of a nomogram predicting the 
probability of lymph node invasion among patients undergoing radical 
prostatectomy and an extended pelvic lymphadenectomy. Eur Urol, Vol. 49, No. 6, 
2006/03/15, pp. 1019-26; discussion 1026-7. 
Cagiannos, I., P. Karakiewicz, J. A. Eastham, M. Ohori, F. Rabbani, C. Gerigk, V. Reuter, M. 
Graefen, P. G. Hammerer, A. Erbersdobler, H. Huland, P. Kupelian, E. Klein, D. I. 
Quinn, S. M. Henshall, J. J. Grygiel, R. L. Sutherland, P. D. Stricker, C. G. Morash, P. 
T. Scardino & M. W. Kattan (2003) A preoperative nomogram identifying decreased 
risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol, Vol. 170, 
No. 5, pp. 1798-803. 
Cancer_Research_UK (2011) Latest UK Cancer Incidence (2008) and Mortality (2008) 
Summary. 
http://info.cancerresearchuk.org/prod_consump/groups/cr_common/@nre/@sta/documents/
generalcontent/cr_074228.pdf 
Cao, D. L., D. W. Ye, H. L. Zhang, Y. Zhu, Y. X. Wang & X. D. Yao (2010) A multiplex model 
of combining gene-based, protein-based, and metabolite-based with positive and 
negative markers in urine for the early diagnosis of prostate cancer. Prostate, Vol., 
No. 2010/10/20, pp. 
D'Amico, A. V., R. Whittington, S. B. Malkowicz, J. Fondurulia, M. H. Chen, I. Kaplan, C. J. 
Beard, J. E. Tomaszewski, A. A. Renshaw, A. Wein & C. N. Coleman (1999) 
Pretreatment nomogram for prostate-specific antigen recurrence after radical 
prostatectomy or external-beam radiation therapy for clinically localized prostate 
cancer. J Clin Oncol, Vol. 17, No. 1, pp. 168-72. 
Deras, I. L., S. M. Aubin, A. Blase, J. R. Day, S. Koo, A. W. Partin, W. J. Ellis, L. S. Marks, Y. 
Fradet, H. Rittenhouse & J. Groskopf (2008) PCA3: a molecular urine assay for 
predicting prostate biopsy outcome. J Urol, Vol. 179, No. 4, 2008/02/26, pp. 1587-92. 
Epstein, J. I., M. J. Carmichael, A. W. Partin & P. C. Walsh (1994) Small high grade 
adenocarcinoma of the prostate in radical prostatectomy specimens performed for 
nonpalpable disease: pathogenetic and clinical implications. J Urol, Vol. 151, No. 6, 
pp. 1587-92. 
Gallina, A., F. K. Chun, A. Briganti, S. F. Shariat, F. Montorsi, A. Salonia, A. Erbersdobler, P. 
Rigatti, L. Valiquette, H. Huland, M. Graefen & P. I. Karakiewicz (2007) 
Development and split-sample validation of a nomogram predicting the 
probability of seminal vesicle invasion at radical prostatectomy. Eur Urol, Vol. 52, 
No. 1, pp. 98-105. 
Graefen, M., A. Haese, U. Pichlmeier, P. G. Hammerer, J. Noldus, K. Butz, A. Erbersdobler, 
R. P. Henke, U. Michl, S. Fernandez & H. Huland (2001) A validated strategy for 
side specific prediction of organ confined prostate cancer: a tool to select for nerve 
sparing radical prostatectomy. J Urol, Vol. 165, No. 3, pp. 857-63. 
Greene, K. L., M. V. Meng, E. P. Elkin, M. R. Cooperberg, D. J. Pasta, M. W. Kattan, K. 
Wallace & P. R. Carroll (2004) Validation of the Kattan preoperative nomogram for 
prostate cancer recurrence using a community based cohort: results from cancer of 
the prostate strategic urological research endeavor (capsure). J Urol, Vol. 171, No. 6 
Pt 1, pp. 2255-9. 
www.intechopen.com
 
Prostate Biopsy 74
Heidenreich, A., J. Bellmunt, M. Bolla, S. Joniau, M. Mason, V. Matveev, N. Mottet, H. P. 
Schmid, T. van der Kwast, T. Wiegel & F. Zattoni (2010) EAU Guidelines on 
Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised 
Disease. Eur Urol, Vol., No. 2010/11/09, pp. 
Kattan, M. W., J. A. Eastham, A. M. Stapleton, T. M. Wheeler & P. T. Scardino (1998) A 
preoperative nomogram for disease recurrence following radical prostatectomy for 
prostate cancer. J Natl Cancer Inst, Vol. 90, No. 10, pp. 766-71. 
Kattan, M. W., J. A. Eastham, T. M. Wheeler, N. Maru, P. T. Scardino, A. Erbersdobler, M. 
Graefen, H. Huland, H. Koh, S. F. Shariat, K. M. Slawin & M. Ohori (2003) Counseling 
men with prostate cancer: a nomogram for predicting the presence of small, 
moderately differentiated, confined tumors. J Urol, Vol. 170, No. 5, pp. 1792-7. 
Koh, H., M. W. Kattan, P. T. Scardino, K. Suyama, N. Maru, K. Slawin, T. M. Wheeler & M. 
Ohori (2003) A nomogram to predict seminal vesicle invasion by the extent and 
location of cancer in systematic biopsy results. J Urol, Vol. 170, No. 4 Pt 1, pp. 1203-8. 
Lughezzani, G., L. Budaus, H. Isbarn, M. Sun, P. Perrotte, A. Haese, F. K. Chun, T. Schlomm, 
T. Steuber, H. Heinzer, H. Huland, F. Montorsi, M. Graefen & P. I. Karakiewicz 
(2010) Head-to-head comparison of the three most commonly used preoperative 
models for prediction of biochemical recurrence after radical prostatectomy. Eur 
Urol, Vol. 57, No. 4, 2009/12/19, pp. 562-8. 
Makarov, D. V., B. J. Trock, E. B. Humphreys, L. A. Mangold, P. C. Walsh, J. I. Epstein & A. W. 
Partin (2007) Updated nomogram to predict pathologic stage of prostate cancer given 
prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) 
based on cases from 2000 to 2005. Urology, Vol. 69, No. 6, pp. 1095-101. 
Marks, L. S., Y. Fradet, I. L. Deras, A. Blase, J. Mathis, S. M. Aubin, A. T. Cancio, M. 
Desaulniers, W. J. Ellis, H. Rittenhouse & J. Groskopf (2007) PCA3 molecular urine 
assay for prostate cancer in men undergoing repeat biopsy. Urology, Vol. 69, No. 3, 
pp. 532-5. 
Mottet, N., J. Bellmunt, M. Bolla, S. Joniau, M. Mason, V. Matveev, H. P. Schmid, T. Van der 
Kwast, T. Wiegel, F. Zattoni & A. Heidenreich (2011) EAU Guidelines on Prostate 
Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant 
Prostate Cancer. Eur Urol, Vol., No. 2011/02/15, pp. 
Nielsen, M. E., S. F. Shariat, P. I. Karakiewicz, Y. Lotan, C. G. Rogers, G. E. Amiel, P. J. 
Bastian, A. Vazina, A. Gupta, S. P. Lerner, A. I. Sagalowsky, M. P. Schoenberg & G. 
S. Palapattu (2007) Advanced age is associated with poorer bladder cancer-specific 
survival in patients treated with radical cystectomy. Eur Urol, Vol. 51, No. 3, 
2006/11/23, pp. 699-706; discussion 706-8. 
Nyberg, M., D. Ulmert, A. Lindgren, U. Lindstrom, P. A. Abrahamsson & A. Bjartell (2010) 
PCA3 as a diagnostic marker for prostate cancer: a validation study on a Swedish 
patient population. Scand J Urol Nephrol, Vol. 44, No. 6, 2010/10/22, pp. 378-83. 
Oesterling, J. E., W. H. Cooner, S. J. Jacobsen, H. A. Guess & M. M. Lieber (1993) Influence of 
patient age on the serum PSA concentration. An important clinical observation. 
Urol Clin North Am, Vol. 20, No. 4, pp. 671-80. 
Ohori, M., M. W. Kattan, H. Koh, N. Maru, K. M. Slawin, S. Shariat, M. Muramoto, V. E. 
Reuter, T. M. Wheeler & P. T. Scardino (2004) Predicting the presence and side of 
extracapsular extension: a nomogram for staging prostate cancer. J Urol, Vol. 171, 
No. 5, pp. 1844-9; discussion 1849. 
Partin, A. W., M. W. Kattan, E. N. Subong, P. C. Walsh, K. J. Wojno, J. E. Oesterling, P. T. 
Scardino & J. D. Pearson (1997) Combination of prostate-specific antigen, clinical 
www.intechopen.com
The Use of Models to Predict the Presence and  
Aggressiveness of Prostate Cancer on Prostate Biopsy 75 
stage, and Gleason score to predict pathological stage of localized prostate cancer. 
A multi-institutional update. Jama, Vol. 277, No. 18, pp. 1445-51. 
Partin, A. W., L. A. Mangold, D. M. Lamm, P. C. Walsh, J. I. Epstein & J. D. Pearson (2001) 
Contemporary update of prostate cancer staging nomograms (Partin Tables) for the 
new millennium. Urology, Vol. 58, No. 6, pp. 843-8. 
Reed, A. B. & D. J. Parekh (2010) Biomarkers for prostate cancer detection. Expert Rev 
Anticancer Ther, Vol. 10, No. 1, 2009/12/18, pp. 103-14. 
Ross, P. L., C. Gerigk, M. Gonen, O. Yossepowitch, I. Cagiannos, P. C. Sogani, P. T. Scardino 
& M. W. Kattan (2002) Comparisons of nomograms and urologists' predictions in 
prostate cancer. Semin Urol Oncol, Vol. 20, No. 2, 2002/05/16, pp. 82-8. 
Roupret, M., V. Hupertan, E. Comperat, S. J. Drouin, V. Phe, E. Xylinas, D. Demanse, M. 
Sibony, F. Richard & O. Cussenot (2009) Cross-cultural validation of a prognostic 
tool: example of the Kattan preoperative nomogram as a predictor of prostate 
cancer recurrence after radical prostatectomy. BJU Int, Vol. 104, No. 6, 2009/03/04, 
pp. 813-7; discussion 817-8. 
Schroder, F. H., J. Hugosson, M. J. Roobol, T. L. Tammela, S. Ciatto, V. Nelen, M. 
Kwiatkowski, M. Lujan, H. Lilja, M. Zappa, L. J. Denis, F. Recker, A. Berenguer, L. 
Maattanen, C. H. Bangma, G. Aus, A. Villers, X. Rebillard, T. van der Kwast, B. G. 
Blijenberg, S. M. Moss, H. J. de Koning & A. Auvinen (2009) Screening and 
prostate-cancer mortality in a randomized European study. N Engl J Med, Vol. 360, 
No. 13, 2009/03/20, pp. 1320-8. 
Schroder, F. H., I. van der Cruijsen-Koeter, H. J. de Koning, A. N. Vis, R. F. Hoedemaeker & 
R. Kranse (2000) Prostate cancer detection at low prostate specific antigen. J Urol, 
Vol. 163, No. 3, pp. 806-12. 
Schumacher, F. R., S. I. Berndt, A. Siddiq, K. B. Jacobs, Z. Wang, S. Lindstrom, V. L. Stevens, C. 
Chen, A. M. Mondul, R. C. Travis, D. O. Stram, R. A. Eeles, D. F. Easton, G. Giles, J. L. 
Hopper, D. E. Neal, F. C. Hamdy, J. L. Donovan, K. Muir, A. Amin Al Olama, Z. 
Kote-Jarai, M. Guy, G. Severi, H. Gronberg, W. B. Isaacs, R. Karlsson, F. Wiklund, J. 
Xu, N. E. Allen, G. L. Andriole, A. Barricarte, H. Boeing, H. B. Bueno-de-Mesquita, E. 
D. Crawford, W. R. Diver, C. A. Gonzalez, J. M. Gaziano, E. L. Giovannucci, M. 
Johansson, L. Le Marchand, J. Ma, S. Sieri, P. Stattin, M. J. Stampfer, A. Tjonneland, P. 
Vineis, J. Virtamo, U. Vogel, S. J. Weinstein, M. Yeager, M. J. Thun, L. N. Kolonel, B. 
E. Henderson, D. Albanes, R. B. Hayes, H. S. Feigelson, E. Riboli, D. J. Hunter, S. J. 
Chanock, C. A. Haiman & P. Kraft (2011) Genome-wide association study identifies 
new prostate cancer susceptibility loci. Hum Mol Genet, Vol., No. 2011/07/12, pp. 
Shappell, S. B. (2008) Clinical utility of prostate carcinoma molecular diagnostic tests. Rev 
Urol, Vol. 10, No. 1, 2008/05/13, pp. 44-69. 
Shariat, S. F., J. A. Karam, J. Walz, C. G. Roehrborn, F. Montorsi, V. Margulis, F. Saad, K. M. 
Slawin & P. I. Karakiewicz (2008a) Improved prediction of disease relapse after 
radical prostatectomy through a panel of preoperative blood-based biomarkers. 
Clin Cancer Res, Vol. 14, No. 12, 2008/06/19, pp. 3785-91. 
Shariat, S. F., M. W. Kattan, A. J. Vickers, P. I. Karakiewicz & P. T. Scardino (2009) Critical 
review of prostate cancer predictive tools. Future Oncol, Vol. 5, No. 10, 2009/12/17, 
pp. 1555-84. 
Shariat, S. F., J. Walz, C. G. Roehrborn, A. R. Zlotta, P. Perrotte, N. Suardi, F. Saad & P. I. 
Karakiewicz (2008b) External validation of a biomarker-based preoperative 
nomogram predicts biochemical recurrence after radical prostatectomy. J Clin 
Oncol, Vol. 26, No. 9, 2008/03/20, pp. 1526-31. 
www.intechopen.com
 
Prostate Biopsy 76
Shukla-Dave, A., H. Hricak, M. W. Kattan, D. Pucar, K. Kuroiwa, H. N. Chen, J. Spector, J. 
A. Koutcher, K. L. Zakian & P. T. Scardino (2007) The utility of magnetic resonance 
imaging and spectroscopy for predicting insignificant prostate cancer: an initial 
analysis. BJU Int, Vol. 99, No. 4, 2007/01/17, pp. 786-93. 
Stanford, J. L., L. M. FitzGerald, S. K. McDonnell, E. E. Carlson, L. M. McIntosh, K. Deutsch, L. 
Hood, E. A. Ostrander & D. J. Schaid (2009) Dense genome-wide SNP linkage scan in 
301 hereditary prostate cancer families identifies multiple regions with suggestive 
evidence for linkage. Hum Mol Genet, Vol. 18, No. 10, 2009/03/03, pp. 1839-48. 
Steuber, T., M. Graefen, A. Haese, A. Erbersdobler, F. K. Chun, T. Schlom, P. Perrotte, H. 
Huland & P. I. Karakiewicz (2006) Validation of a nomogram for prediction of side 
specific extracapsular extension at radical prostatectomy. J Urol, Vol. 175, No. 3 Pt 
1, 2006/02/14, pp. 939-44; discussion 944. 
Steyerberg, E. W., M. J. Roobol, M. W. Kattan, T. H. van der Kwast, H. J. de Koning & F. H. 
Schroder (2007) Prediction of indolent prostate cancer: validation and updating of a 
prognostic nomogram. J Urol, Vol. 177, No. 1, pp. 107-12; discussion 112. 
Thompson, I. M., D. P. Ankerst, C. Chi, P. J. Goodman, C. M. Tangen, M. S. Lucia, Z. Feng, 
H. L. Parnes & C. A. Coltman, Jr. (2006) Assessing prostate cancer risk: results from 
the Prostate Cancer Prevention Trial. J Natl Cancer Inst, Vol. 98, No. 8, 2006/04/20, 
pp. 529-34. 
Thompson, I. M., P. J. Goodman, C. M. Tangen, M. S. Lucia, G. J. Miller, L. G. Ford, M. M. 
Lieber, R. D. Cespedes, J. N. Atkins, S. M. Lippman, S. M. Carlin, A. Ryan, C. M. 
Szczepanek, J. J. Crowley & C. A. Coltman, Jr. (2003) The influence of finasteride on 
the development of prostate cancer. N Engl J Med, Vol. 349, No. 3, pp. 215-24. 
Tomlins, S. A., A. Bjartell, A. M. Chinnaiyan, G. Jenster, R. K. Nam, M. A. Rubin & J. A. 
Schalken (2009) ETS gene fusions in prostate cancer: from discovery to daily clinical 
practice. Eur Urol, Vol. 56, No. 2, 2009/05/05, pp. 275-86. 
van den Bergh, R. C., M. J. Roobol, T. Wolters, P. J. van Leeuwen & F. H. Schroder (2008) 
The Prostate Cancer Prevention Trial and European Randomized Study of 
Screening for Prostate Cancer risk calculators indicating a positive prostate biopsy: 
a comparison. BJU Int, Vol. 102, No. 9, 2008/08/22, pp. 1068-73. 
Vickers, A. J. (2008) Decision analysis for the evaluation of diagnostic tests, prediction 
models and molecular markers. Am Stat, Vol. 62, No. 4, 2009/01/10, pp. 314-320. 
Walz, J., A. Gallina, P. Perrotte, C. Jeldres, Q. D. Trinh, G. C. Hutterer, M. Traumann, A. 
Ramirez, S. F. Shariat, M. McCormack, J. P. Perreault, F. Benard, L. Valiquette, F. 
Saad & P. I. Karakiewicz (2007) Clinicians are poor raters of life-expectancy before 
radical prostatectomy or definitive radiotherapy for localized prostate cancer. BJU 
Int, Vol. 100, No. 6, pp. 1254-8. 
Wang, L., H. Hricak, M. W. Kattan, H. N. Chen, K. Kuroiwa, H. F. Eisenberg & P. T. 
Scardino (2007) Prediction of seminal vesicle invasion in prostate cancer: 
incremental value of adding endorectal MR imaging to the Kattan nomogram. 
Radiology, Vol. 242, No. 1, pp. 182-8. 
Wiklund, F. (2010) Prostate cancer genomics: can we distinguish between indolent and fatal 
disease using genetic markers? Genome Med, Vol. 2, No. 7, 2010/07/30, pp. 45. 
Witte, J. S. (2009) Prostate cancer genomics: towards a new understanding. Nat Rev Genet, 
Vol. 10, No. 2, 2008/12/24, pp. 77-82. 
www.intechopen.com
Prostate Biopsy
Edited by Dr. Nabil K. Bissada
ISBN 978-953-307-702-4
Hard cover, 134 pages
Publisher InTech
Published online 02, December, 2011
Published in print edition December, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Prostate Biopsy represents the standard procedure for diagnosing Prostate Cancer. This procedure can be
performed transrectally, through perineum or occasionally through the urethra. Although the procedures of
Prostate Biopsy are covered in numerous publications, there is still a need for gathering different aspects and
methods in one source. Hopefully, this book will help physicians in their effort to provide the best treatment for
their patients.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Ste ́phane Larre ́, Richard Bryant and Freddie Hamdy (2011). The Use of Models to Predict the Presence and
Aggressiveness of Prostate Cancer on Prostate Biopsy, Prostate Biopsy, Dr. Nabil K. Bissada (Ed.), ISBN: 978-
953-307-702-4, InTech, Available from: http://www.intechopen.com/books/prostate-biopsy/the-use-of-models-
to-predict-the-presence-and-aggressiveness-of-prostate-cancer-on-prostate-biopsy
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
